When making my last purchase of BDAL, did I mention it has a history of preannouncing a good quarter? I did.
>>BILLERICA, Mass.--(BW HealthWire)--July 9, 2001--Bruker Daltonics Inc. (NASDAQ: BDAL - news) today announced that new order bookings for its life-science systems based on mass spectrometry continued to be robust in the second quarter of 2001, which ended on June 30, 2001. Life-science systems bookings for the second quarter 2001 have increased more than 25% compared to the second quarter 2000. Subject to the cautionary statement below, Bruker Daltonics continues to expect top-line product revenue growth of 25% and EPS growth of 50% for the full year 2001, compared to 2000.
``In light of recent questions about growth patterns in life-science mass spectrometry, we have again examined our new order bookings for life-science systems after the end of the second quarter'', stated Frank H. Laukien, Ph.D., President and Chief Executive Officer. ``Demand for our high-performance products is growing, and our many recent product introductions for genotyping and proteomics are being well accepted by customers. We are very pleased to again report significant growth in demand for our life-science research and drug discovery systems.''<<
snip
Cheers, Tuck |
